Announced Fri, 26 Jun · 19:02 IST
Wanbury board OKs new subsidiary, names EY as internal auditor for FY27
Management Changes View source PDF
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.8%1-day move
₹275.00
prior close
₹274.35
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2+1.0+1.1+2.2+1.8+4.8+3.9+3.7+3.5-1.3+24.0———
Up moveDown movePending
AI summary
Wanbury Limited's board on June 26, 2026 approved three items. First, incorporating 'Wanbury Skin Health Limited' as a subsidiary in India in the pharma space, with Wanbury holding 82 percent via 41,000 shares at Rs 10 face value, investing about Rs 4.10 lakh. Second, appointing Ernst and Young LLP as Internal Auditor for FY 2026-27. Third, appointing ABK and Associates as Cost Auditor for FY 2026-27, both for a one-year term.
Likely market impact
Small Rs 4.10 lakh outlay into a skin health subsidiary; auditor appointments are routine and unlikely to move the stock.